ERs receiving Obex® achieved a decrease in triglyceride, insulin and insulin resistance (HOMA-IR) levels at the end of the trial, as well as an improvement in insulin sensitivity and β-cell function (HOMA-β) with respect to baseline values and Obex® early non-responders (ENRs), which did not occur for ERs in the placebo group, with the exception of triglycerides and cholesterol. This evidence concerns the gene INS and Insulin resistance.